Vyjuvek® (Beramagene Geperpavec-Svdt) – Commercial Medical Benefit Drug Policyopen_in_new

Vyjuvek is covered only for topical treatment of wounds in patients ≥6 months with dystrophic epidermolysis bullosa who have a documented COL7A1 mutation and treated wounds with adequate granulation, excellent vascularization, no active infection and no current/history of squamous cell carcinoma; age <6 months, absent COL7A1 mutation, infected or poorly granulated wounds, SCC presence/history, or use on the same wound(s) as Filsuvez are excluded. Key requirements: prescription by or consultation with a dermatologist experienced in DEB, dosing per FDA labeling, submission of medical records confirming diagnosis/mutation and wound characteristics, initial/renewal limits of up to 12 months and 52 doses, and continuation requires prior Vyjuvek use with documented clinical response.

"Vyjuvek is proven and medically necessary for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who meet all of the following criteria:"